JP6535101B2 - 抗心筋虚血再灌流傷害の香青蘭活性成分組成物 - Google Patents
抗心筋虚血再灌流傷害の香青蘭活性成分組成物 Download PDFInfo
- Publication number
- JP6535101B2 JP6535101B2 JP2017548507A JP2017548507A JP6535101B2 JP 6535101 B2 JP6535101 B2 JP 6535101B2 JP 2017548507 A JP2017548507 A JP 2017548507A JP 2017548507 A JP2017548507 A JP 2017548507A JP 6535101 B2 JP6535101 B2 JP 6535101B2
- Authority
- JP
- Japan
- Prior art keywords
- luteolin
- cells
- hypoxia
- kaempferol
- glucoside
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title claims description 17
- 206010063837 Reperfusion injury Diseases 0.000 title claims description 8
- 208000031225 myocardial ischemia Diseases 0.000 title claims description 8
- 239000004480 active ingredient Substances 0.000 title claims description 7
- 241000608170 Gymnadenia conopsea Species 0.000 title description 2
- KBGKQZVCLWKUDQ-UHFFFAOYSA-N luteolin-glucoside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC(O)=CC2=C1C(=O)C=C(C=1C=C(O)C(O)=CC=1)O2 KBGKQZVCLWKUDQ-UHFFFAOYSA-N 0.000 claims description 37
- IYRMWMYZSQPJKC-UHFFFAOYSA-N kaempferol Chemical compound C1=CC(O)=CC=C1C1=C(O)C(=O)C2=C(O)C=C(O)C=C2O1 IYRMWMYZSQPJKC-UHFFFAOYSA-N 0.000 claims description 28
- 239000003814 drug Substances 0.000 claims description 27
- IVCZEZUJCMWBBR-UHFFFAOYSA-N 7-O-beta-D-glucopyranosyl-7,3',4'-trihydroxyflavone Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C2C(=O)C=C(C=3C=C(O)C(O)=CC=3)OC2=C1 IVCZEZUJCMWBBR-UHFFFAOYSA-N 0.000 claims description 24
- QZOVLVSTWSTHQN-UHFFFAOYSA-N luteolin 7-O-glucoside Natural products OCC1OC(Oc2cc(O)c3C(=O)C=C(C(=O)c3c2)c4ccc(O)c(O)c4)C(O)C(O)C1O QZOVLVSTWSTHQN-UHFFFAOYSA-N 0.000 claims description 24
- 235000008777 kaempferol Nutrition 0.000 claims description 22
- IQPNAANSBPBGFQ-UHFFFAOYSA-N luteolin Chemical compound C=1C(O)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(O)C(O)=C1 IQPNAANSBPBGFQ-UHFFFAOYSA-N 0.000 claims description 22
- 235000009498 luteolin Nutrition 0.000 claims description 22
- PEFNSGRTCBGNAN-QNDFHXLGSA-N luteolin 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C=C(C=3C=C(O)C(O)=CC=3)OC2=C1 PEFNSGRTCBGNAN-QNDFHXLGSA-N 0.000 claims description 22
- YPWHZCPMOQGCDQ-HMGRVEAOSA-N Kaempferol-7-O-glucoside Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C(O)=C(C=3C=CC(O)=CC=3)OC2=C1 YPWHZCPMOQGCDQ-HMGRVEAOSA-N 0.000 claims description 16
- YPWHZCPMOQGCDQ-UHFFFAOYSA-N Populnin Natural products OC1C(O)C(O)C(CO)OC1OC1=CC(O)=C2C(=O)C(O)=C(C=3C=CC(O)=CC=3)OC2=C1 YPWHZCPMOQGCDQ-UHFFFAOYSA-N 0.000 claims description 16
- BBFYUPYFXSSMNV-UHFFFAOYSA-N quercetin-7-o-galactoside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC(O)=C2C(=O)C(O)=C(C=3C=C(O)C(O)=CC=3)OC2=C1 BBFYUPYFXSSMNV-UHFFFAOYSA-N 0.000 claims description 16
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 claims description 13
- LRDGATPGVJTWLJ-UHFFFAOYSA-N luteolin Natural products OC1=CC(O)=CC(C=2OC3=CC(O)=CC(O)=C3C(=O)C=2)=C1 LRDGATPGVJTWLJ-UHFFFAOYSA-N 0.000 claims description 7
- UBSCDKPKWHYZNX-UHFFFAOYSA-N Demethoxycapillarisin Natural products C1=CC(O)=CC=C1OC1=CC(=O)C2=C(O)C=C(O)C=C2O1 UBSCDKPKWHYZNX-UHFFFAOYSA-N 0.000 claims description 6
- UXOUKMQIEVGVLY-UHFFFAOYSA-N morin Natural products OC1=CC(O)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UXOUKMQIEVGVLY-UHFFFAOYSA-N 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 238000009472 formulation Methods 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims description 2
- 210000004027 cell Anatomy 0.000 description 47
- 206010021143 Hypoxia Diseases 0.000 description 36
- 230000006378 damage Effects 0.000 description 32
- 208000027418 Wounds and injury Diseases 0.000 description 30
- 230000007954 hypoxia Effects 0.000 description 30
- 208000014674 injury Diseases 0.000 description 30
- 210000004413 cardiac myocyte Anatomy 0.000 description 22
- 229940079593 drug Drugs 0.000 description 20
- 230000000694 effects Effects 0.000 description 19
- 229910052757 nitrogen Inorganic materials 0.000 description 13
- 239000000243 solution Substances 0.000 description 13
- 239000006228 supernatant Substances 0.000 description 13
- 241000700159 Rattus Species 0.000 description 12
- 239000001301 oxygen Substances 0.000 description 12
- 229910052760 oxygen Inorganic materials 0.000 description 12
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 11
- 239000007789 gas Substances 0.000 description 11
- 239000002609 medium Substances 0.000 description 11
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 10
- 238000004458 analytical method Methods 0.000 description 9
- 239000012530 fluid Substances 0.000 description 9
- 150000001875 compounds Chemical class 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 230000001146 hypoxic effect Effects 0.000 description 6
- 230000001681 protective effect Effects 0.000 description 6
- 230000004044 response Effects 0.000 description 6
- 229920006395 saturated elastomer Polymers 0.000 description 6
- 238000010586 diagram Methods 0.000 description 5
- 239000006481 glucose medium Substances 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 210000003205 muscle Anatomy 0.000 description 5
- 102000029816 Collagenase Human genes 0.000 description 4
- 108060005980 Collagenase Proteins 0.000 description 4
- 241000700157 Rattus norvegicus Species 0.000 description 4
- 102000004142 Trypsin Human genes 0.000 description 4
- 108090000631 Trypsin Proteins 0.000 description 4
- 229960002424 collagenase Drugs 0.000 description 4
- 238000012258 culturing Methods 0.000 description 4
- 102000038379 digestive enzymes Human genes 0.000 description 4
- 108091007734 digestive enzymes Proteins 0.000 description 4
- 239000012588 trypsin Substances 0.000 description 4
- 230000002861 ventricular Effects 0.000 description 4
- 230000035899 viability Effects 0.000 description 4
- 230000003698 anagen phase Effects 0.000 description 3
- 230000003293 cardioprotective effect Effects 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 230000002950 deficient Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 239000011259 mixed solution Substances 0.000 description 3
- 230000002107 myocardial effect Effects 0.000 description 3
- 239000011555 saturated liquid Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 241000233855 Orchidaceae Species 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 229910001424 calcium ion Inorganic materials 0.000 description 2
- 230000001964 calcium overload Effects 0.000 description 2
- 238000013329 compounding Methods 0.000 description 2
- 230000008602 contraction Effects 0.000 description 2
- 230000001120 cytoprotective effect Effects 0.000 description 2
- 230000003511 endothelial effect Effects 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 241000411851 herbal medicine Species 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 230000002427 irreversible effect Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 210000004165 myocardium Anatomy 0.000 description 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000005211 surface analysis Methods 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 239000005541 ACE inhibitor Substances 0.000 description 1
- 101710129690 Angiotensin-converting enzyme inhibitor Proteins 0.000 description 1
- 101710086378 Bradykinin-potentiating and C-type natriuretic peptides Proteins 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 108090000932 Calcitonin Gene-Related Peptide Proteins 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- 235000011511 Diospyros Nutrition 0.000 description 1
- 244000236655 Diospyros kaki Species 0.000 description 1
- 244000179525 Dracocephalum moldavica Species 0.000 description 1
- 235000010700 Dracocephalum moldavica Nutrition 0.000 description 1
- 229940123457 Free radical scavenger Drugs 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 208000007201 Myocardial reperfusion injury Diseases 0.000 description 1
- 108010011536 PTEN Phosphohydrolase Proteins 0.000 description 1
- 244000131316 Panax pseudoginseng Species 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 102100032543 Phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN Human genes 0.000 description 1
- RXUWDKBZZLIASQ-UHFFFAOYSA-N Puerarin Natural products OCC1OC(Oc2c(O)cc(O)c3C(=O)C(=COc23)c4ccc(O)cc4)C(O)C(O)C1O RXUWDKBZZLIASQ-UHFFFAOYSA-N 0.000 description 1
- 102100033019 Tyrosine-protein phosphatase non-receptor type 11 Human genes 0.000 description 1
- 101710116241 Tyrosine-protein phosphatase non-receptor type 11 Proteins 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 239000012930 cell culture fluid Substances 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000002301 combined effect Effects 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 210000001700 mitochondrial membrane Anatomy 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 230000003680 myocardial damage Effects 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 229960001597 nifedipine Drugs 0.000 description 1
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 1
- -1 oxygen free radical Chemical class 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229930015704 phenylpropanoid Natural products 0.000 description 1
- 125000001474 phenylpropanoid group Chemical group 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000003223 protective agent Substances 0.000 description 1
- HKEAFJYKMMKDOR-VPRICQMDSA-N puerarin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=C(O)C=CC(C2=O)=C1OC=C2C1=CC=C(O)C=C1 HKEAFJYKMMKDOR-VPRICQMDSA-N 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 150000003648 triterpenes Chemical class 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 239000000304 virulence factor Substances 0.000 description 1
- 230000007923 virulence factor Effects 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Molecular Biology (AREA)
- Mycology (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Description
対数増殖期のH9c2ラット心筋細胞を消化した後、DMEM培地(含む10%FBS)で再懸濁し、96ウェルプレートに接種し、37℃にて5%CO2のインキュベーターに正常に培養する。細胞が対数増殖期になってから、下記の組分けに従い実験が行われる。(1)正常培養組(Control組):実験中に、通常の培地に37℃にて5%CO2のインキュベーターに正常に培養する。(2)N2H/Rモデル組(モデル組):対数増殖期になった実験用の細胞を通常の培養液のかわりに、予めに95%N2+5%CO2の混合されたガスを1時間に無糖Earle’s液(イーグル液)に注入して飽和させたものを利用し、その後に37℃にて95%N2+5%CO2の定温インキュベーターに入れ、低酸素で6時間に培養し、酸欠された心筋細胞を予めに95%空気+5%CO2の混合されたガスをDMEM高グルコース培地(10%FBSを含む)に注入して飽和させ、通常の培養条件に5時間にて酸素を回復する。(3)ルテオリン、ケンペロールおよびルテオリン7-O-グルコシド配合前処理組:H9c2ラット心筋細胞が異なるルテオリン、ケンペロールおよびルテオリン7-O-グルコシドの配合比率により予め12時間にて培養されてから、通常の培養液のかわりに、95%N2+5%CO2の混合されたガスを1時間に無糖Earle’s液に注入して飽和させたものを利用し、N2低酸素タンクで6時間に低酸素処理してから、通常の培養液で通常の培養条件に5時間にて酸素を回復すると共に、各配合薬物を投入して培養する。各実験組の細胞を処理した後に、20μg/ mlのMTTを添加し4時間にて培養し、150μlのDMSOでMTTを溶解する。酵素免疫検知器によって波長が490nmである箇所に各ウェルのODを測定する。更に細胞の活性力を計算する。実験結果は表2に示す通りである。
無菌状態で生まれた二日のWistarラット乳児の心室筋を取り出し、混合消化酵素(0.06%のトリプシンと0.1%のII型コラゲナーゼの均量混合液)で短時間に複数回に繰り返し消化する。差動付着法で心筋細胞を純化する。細胞の数をカウントし、生きている細胞数と細胞の生存率が得られ、1.0×106cell/mLで培地をプレートに滴下する。細胞を24時間に培養した後、上清液を捨て、PBSで三回洗い、細胞を比較組、低酸素/再酸素化傷害組、低酸素/再酸素化傷害モデル+配合組1(30uM)、低酸素/再酸素化傷害モデル+配合組3(30uM)、低酸素/再酸素化傷害モデル+配合組11(30uM)、低酸素/再酸素化傷害モデル+ルテオリン(30uM)、低酸素/再酸素化傷害モデル+ケンペロール(30uM)、低酸素/再酸素化傷害モデル+ルテオリン-7-O-グルコシド(30uM)に分ける。全ての低酸素/再酸素化傷害組に予めに薬剤を24時間に投与した後、予めに95%N2+5%CO2の混合されたガスを1時間に無糖Earle’s液に注入して飽和させた液体に入れた後に、37℃にて95%N2+5%CO2の定温インキュベーターに入れ、低酸素で6時間に培養し、酸欠された心筋細胞を予めに95%空気+5%CO2の混合されたガスをDMEM高グルコース培地(10%FBSを含む)に注入して飽和させた培地により、通常の培養条件に5時間にて酸素を回復すると共に、各配合薬物を投入し培養する。各実験組の細胞を処理した後に、20μg/ mlのMTTを添加し4時間にて培養し、150μlのDMSOでMTTを溶解する。酵素免疫検知器によって波長が490nmである箇所に各ウェルのODを測定する。更に細胞の活性力を計算する。実験結果は表4に示す通りである。
Claims (3)
- 有効成分及び薬学的に許容されるキャリアを含む配合医薬組成物であって、
前記有効成分は、ルテオリンとケンペロールとルテオリン-7-O-グルコシドを含み、
前記ルテオリンと前記ケンペロールと前記ルテオリン-7-O-グルコシドのモル比が0.7-2.2:2.1-4.1:0.6-2.4であることを特徴とする心筋虚血再灌流傷害を治療するための配合医薬組成物。 - 前記ルテオリンと前記ケンペロールと前記ルテオリン-7-O-グルコシドのモル比が1.1-1.6:2.8-3.5:1.0-1.7であることを特徴とする請求項1に記載の配合医薬組成物。
- 請求項1又は2に記載される配合医薬組成物を使用し、心筋虚血再灌流傷害を治療する医薬を調製する調製方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410724953.2A CN104490910B (zh) | 2014-12-03 | 2014-12-03 | 一种抗心肌缺血再灌注损伤的香青兰活性成分组合物 |
CN201410724953.2 | 2014-12-03 | ||
PCT/CN2015/073822 WO2016086543A1 (zh) | 2014-12-03 | 2015-03-06 | 一种抗心肌缺血再灌注损伤的香青兰活性成分组合物 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2017537167A JP2017537167A (ja) | 2017-12-14 |
JP6535101B2 true JP6535101B2 (ja) | 2019-06-26 |
Family
ID=52932424
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017548507A Active JP6535101B2 (ja) | 2014-12-03 | 2015-03-06 | 抗心筋虚血再灌流傷害の香青蘭活性成分組成物 |
Country Status (5)
Country | Link |
---|---|
US (1) | US10369165B2 (ja) |
EP (1) | EP3228316A4 (ja) |
JP (1) | JP6535101B2 (ja) |
CN (1) | CN104490910B (ja) |
WO (1) | WO2016086543A1 (ja) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112353794B (zh) * | 2020-12-15 | 2024-05-14 | 河北医科大学第二医院 | 一种治疗脑梗死疾病的药物组合物及其应用 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090074895A1 (en) * | 2005-05-02 | 2009-03-19 | Vanadis Bioscience Ltd | Composition and uses thereof |
CN100569241C (zh) * | 2007-01-17 | 2009-12-16 | 北京天川军威医药技术开发有限公司 | 芹菜籽乙酸乙酯萃取物及其用途 |
CN101219161B (zh) * | 2007-12-25 | 2011-09-14 | 新疆维吾尔自治区药物研究所 | 香青兰提取物和香青兰滴丸及其生产方法 |
CN102670583A (zh) * | 2012-06-11 | 2012-09-19 | 新疆德泓生物科技有限公司 | 香青兰中黄酮化合物在制备抗心肌缺血药物中的应用 |
CN102697769A (zh) * | 2012-06-11 | 2012-10-03 | 新疆德泓生物科技有限公司 | 源自香青兰的化合物用于抗心肌缺血再灌注损伤的用途 |
-
2014
- 2014-12-03 CN CN201410724953.2A patent/CN104490910B/zh active Active
-
2015
- 2015-03-06 US US15/531,763 patent/US10369165B2/en active Active
- 2015-03-06 JP JP2017548507A patent/JP6535101B2/ja active Active
- 2015-03-06 WO PCT/CN2015/073822 patent/WO2016086543A1/zh active Application Filing
- 2015-03-06 EP EP15866026.6A patent/EP3228316A4/en active Pending
Also Published As
Publication number | Publication date |
---|---|
EP3228316A4 (en) | 2018-04-25 |
JP2017537167A (ja) | 2017-12-14 |
US20170266216A1 (en) | 2017-09-21 |
CN104490910B (zh) | 2017-05-31 |
US10369165B2 (en) | 2019-08-06 |
WO2016086543A1 (zh) | 2016-06-09 |
EP3228316A1 (en) | 2017-10-11 |
CN104490910A (zh) | 2015-04-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3549589A1 (en) | Pharmaceutical composition containing mitochondria | |
KR102459500B1 (ko) | 퀘르세틴 배당체를 함유하는 근위축 억제제 | |
Wu et al. | Pharmacokinetics of (±)‐,(+)‐, and (−)‐gossypol in humans and dogs | |
Huang et al. | Geraniin protects bone marrow‑derived mesenchymal stem cells against hydrogen peroxide‑induced cellular oxidative stress in vitro | |
KR101864009B1 (ko) | 레드비트 추출물을 이용한 방사선에 의한 면역조혈기능 장해 방호용 조성물 | |
JP6535101B2 (ja) | 抗心筋虚血再灌流傷害の香青蘭活性成分組成物 | |
JP2022534165A (ja) | ニコチンアミドモノヌクレオチド及びモグロシドを含む組成物とその使用法 | |
WO2021222700A1 (en) | Compositions and methods for treating cancer with andrographolide and melatonin combination therapy | |
CN105949156A (zh) | 一种伊曲康唑的药物组合物及其医药用途 | |
CA2884644A1 (en) | Tetrandrine pharmaceutical formulations and method | |
CN102526227A (zh) | 藏边大黄提取物在制备防治脂肪性肝病药物中的应用 | |
CN103565797B (zh) | 用于抑制运动神经元自体吞噬的医药组合物及其应用 | |
KR101682156B1 (ko) | 레드비트 추출물을 이용한 방사선에 의한 면역조혈기능 장해 방호용 조성물 | |
KR101603279B1 (ko) | 프로토베르베린 유도체 또는 이의 약학적으로 허용가능한 염을 유효성분으로 함유하는 nfat5의 활성 관련 질환의 예방 또는 치료용 약학적 조성물 | |
US20080050426A1 (en) | Method For Preparing Extract From Wild Ginseng Showing Anticancer Activity And The Composition Comprising The Same | |
US9540378B2 (en) | Composition comprising purine derivatives or salt thereof for preventing or treating atopic dermatitis | |
Ju et al. | Clinical tolerability and pharmacokinetics of Erigerontis hydroxybenzene injection: Results of a randomized phase I study in healthy Chinese volunteers | |
CN106083590A (zh) | 磷酸肌酸钠的药物组合物及其在生物医药中的应用 | |
WO2008010668A1 (en) | 20(s -ginsenoside rg3 as an anti-angiogenic composition | |
Kim et al. | Solanum nigrum Line inhibits osteoclast differentiation and suppresses bone mineral density reduction in the ovariectomy‑induced osteoporosis model | |
CN116785417B (zh) | 芦荟苷与her2-car-t细胞联合制备治疗骨肉瘤的药物 | |
CN115607606B (zh) | 辣椒来源纳米囊泡在制备防治动脉粥样硬化疾病药物中的应用 | |
US20230190677A1 (en) | Pharmaceutical composition for preventing or treating aging-related diseases | |
KR100315200B1 (ko) | 데옥시포도필로톡신을유효성분으로함유하는고형암치료제조성물 | |
CN102850427B (zh) | 丹参酮ⅱa衍生物及其制备和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20170602 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20180206 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180501 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20181002 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190201 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20190201 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20190404 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20190514 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20190530 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6535101 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |